tbuckley/cabot-search huggingface dataset:
Bempedoic Acid for Lowering LDL Cholesterol
Authors: Michael C. Honigberg, Pradeep Natarajan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION
Authors: Naema Nayyar, David Shih, Ivanna Bihun, Ibiayi Dagogo-Jack, Corey Gill, Elisa Aquilanti, Mia Bertalan, Alexander Kaplan, Megan D’Andrea, Ugonma Chukwueke, Franziska Ippen, Christopher Alvarez-Breckenridge, Nicholas Camarda, Matthew Lastrapes, Devin McCabe, Benjamin Kuter, Benjamin Kaufman, Matthew Strickland, Juan Carlos Martinez-Gutierrez, Deepika Nagabhushan, Magali De Sauvage, Michael White, Brandyn Castro, Kaitlin Hoang, Andrew Kaneb, Emily Batchelor, Sun Ha Paek, Sung-Hye Park, Maria Martinez-Lage, Anna Berghoff, Parker Merrill, Elizabeth Gerstner, Tracy Batchelor, Matthew Frosch, Ryan Frazier, Darrell Borger, A John Iafrate, Bruce Johnson, Sandro Santagata, Matthias Preusser, Daniel Cahill, Scott Carter, Priscilla Brastianos
Journal: Neuro-Oncology (2019)

Abstract Although lung adenocarcinomas frequently metastasize to the brain, treatment options for lung adenocarcinoma brain metastases are limited. We discovered novel candidate drivers of progression by using case-control analyses to compare whole-exome sequencing data from a cohort of 73 lung adenocarcinoma brain metastases to a control cohort of 503 primary lung adenocarcinomas. We identified 3 genomic regions with significantly more frequent amplifications in brain metastases compared to the control cohort: MYC (12% vs 6%), YAP1 (7% vs 0.8%) and MMP13 (10% vs 0.6%). We also identified CDKN2A/B as a region deleted at a significantly greater frequency in brain metastases compared to primary lung adenocarcinomas (27% vs 13%, respectively). We confirmed frequent amplifications of MYC and YAP1/MMP13 in an independent validation cohort of 105 lung adenocarcinoma brain metastasis samples using fluorescence in situ hybridization. We further validated that MYC, YAP1 and MMP13 can drive brain metastases in a patient-derived xenograft mouse model. We found a higher incidence of metastases to the brain in mice receiving intracardiac injections of tumor cells expressing the candidate drivers compared to tumor cells expressing LacZ as a control. These results indicate that somatic alterations can drive lung adenocarcinomas to metastasize to the brain. The candidate brain metastasis drivers that we identified may serve as therapeutic targets in patients with lung adenocarcinomas who develop this devastating complication.
More Considerations on Both Model Assumptions and Results Interpretations—Evaluating Readmission—Reply
Authors: Sushant Joshi, Teryl Nuckols, Neeraj Sood
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
Authors: Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael L. Wang, Jon E. Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostic, Daniel Li, Yeonhee Kim, Tanya Siddiqi
Journal: Blood (2019)
Pelvic Inflammatory Disease
Authors: William M. McCormack
Journal: New England Journal of Medicine (1994)

Pelvic inflammatory disease refers to infection of the uterus, fallopian tubes, and adjacent pelvic structures that is not associated with surgery or pregnancy. It is also known as salpingitis. This is an important infection, particularly among disadvantaged women from urban areas. An estimated 1 million American women have pelvic inflammatory disease each year. Long-term sequelae such as infertility occur in about 25 percent13. The direct and indirect costs of the disease and its complications were estimated to exceed $4 billion in 19904.Etiology and PathogenesisPelvic inflammatory disease is almost always an ascending infection in which pathogenic . . .
18F-FDG PET/CT in Graft Versus Host Disease–Associated Polymyositis
Authors: Apurva Sood, Alka Rani Khadwal, Tinu Lukose, Rajender Kumar, Harmandeep Singh, Amanjit Bal, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2019)

Abstract Graft versus host disease (GVHD) is the most frequent and serious complication of allogenic hematopoietic stem cell transplant. Polymyositis is a rare neuromuscular manifestation of GVHD, which often responds well to corticosteroid and immunosuppression therapy. We present a case of a 38-year-old man with a known case of mixed-phenotype acute leukemia after hematopoietic stem cell transplant presenting with GVHD-associated polymyositis. 18 F-FDG PET/CT done in this case not only helped in the detection of the muscle involvement but also helped in obtaining precise muscle sample for histopathological diagnosis using PET-guided biopsy.
CML Patients' Views on Psychological Support throughout the Treatment-Free Remission Journey
Authors: Giora Sharf, Andreas Hochhaus, Jan Geissler, Celia Marin, Zack Pemberton-Whiteley, Felice Bombaci, Rita I O Christensen, Bahija Gouimi, Mina Daban, Nigel B Deekes, Jennie Bradley
Journal: Blood (2019)
Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers
Authors: Fadi Towfic, Naser Ansari-Pour, Maria Ortiz, Sarah Gooding, Dan Rozelle, Victoria Zadorozhny, Konstantinos Mavrommatis, Sneh Lata, Nicholas Stong, Sitharthan Kamalakaran, Kao-Tai Tsai, Erin Flynt, Anjan Thakurta
Journal: Blood (2019)
Perforation of the Heart during Cardiac Catheterization and Selective Angiocardiography
Authors: DORIS J. W. ESCHER, JEROME H. SHAPIRO, BERTA M. RUBINSTEIN, ELLIOTT S. HURWITT, SIDNEY P. SCHWARTZ
Journal: Circulation (1958)

Perforation of the myocardium is rare during cardiac catheterization. The precautions to be exercised, particularly in regard to clinical management, are delineated in this communication.
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Authors: Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie, Austin I Kim, Reid W Merryman, Jessica Lowney, Josie Montegaard, Victoria Patterson, Caron A. Jacobson, Eric D Jacobsen, Ann S. LaCasce, Jon E. Arnason, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids
Journal: Blood (2019)
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy
Authors: Naval G. Daver, Jacqueline S Garcia, Brian A Jonas, Kevin R Kelly, Sarit Assouline, Joseph M Brandwein, Pierre Fenaux, Rebecca L. Olin, Giovanni Martinelli, Stefania Paolini, Arnaud Pigneux, Daniel A Pollyea, Bayard L Powell, Gail J. Roboz, Agostino Tafuri, Norbert Vey, Giuseppe Visani, Karen W.L. Yee, Monique Dail, Cherie Green, Whitney P Kirschbrown, Wan-Jen Hong, Marion G Ott, Maika Onishi, Jue Wang, Marina Y Konopleva, Michael Andreeff
Journal: Blood (2019)
Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide
Authors: Christian Klein, Christian Augsberger, Wei Xu, Christina Heitmüller, Lydia Hanisch, Johannes Sam, Vesna Pulko, Anne Schönle, John Challier, Alejandro Carpy, Nikola Konstandin, Maurine Rothe, Gerulf Hänel, Veit Bücklein, Felix S. Lichtenegger, Antje Tunger, Marc Schmitz, Michael von Bergwelt, Karsten Spiekermann, Pablo Umana, Marion Subklewe
Journal: Blood (2019)
Inpatient Outcomes and Rates of Venous Thromboembolism and Gastrointestinal Bleeding in Patients with Hepatocellular Carcinoma: Results from Nationwide Inpatient Sample Database 2007-2016
Authors: Kamelah Abushalha, Sawsan Abulaimoun, Ryan Walters, Sara Albagoush, Hussain I Rangoonwala, Peter T. Silberstein, Wael Tuqan
Journal: Blood (2019)
NIMG-06. OUR THERAPEUTIC STRATEGIES FOR GLIOBLASTOMA: INTRAOPERATIVE SUPPORT SYSTEMS [INTRAOPERATIVE MRI, PET, 5-AMINOLEVULINIC ACID (5-ALA)] AND NEOADJUVANT CHEMOTHERAPY
Authors: Keisuke Miyake, Daisuke Ogawa, Masaki Okada, Tetsuhiro Hatakeyama, Takashi Tamiya
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Neuronavigation systems with magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging (methionine [MET], fluorothymidine [FLT], and fluoromisonidazole [FMISO]) are routinely used in glioblastoma surgery. Residual tumor identified using intraoperative MRI (IoMRI) or 5-aminolevulinic acid (5-ALA) fluorescence is removed. Neoadjuvant bevacizumab therapy is offered to patients with low Karnovsky performance status (KPS) or with tumors in eloquent regions. We evaluated the usefulness of neoadjuvant bevacizumab therapy. METHODS Twelve patients with glioblastoma with low KPS or tumors in eloquent regions on multiple PET and IoMRI evaluations were enrolled between January 2016 and April 2019. Six had received neoadjuvant bevacizumab before surgery; six had not. Postsurgical 5-ALA fluorescence (strong, vague, and none) tumor extraction rate, residual volume on MRI and PET imaging, and prognosis in the patients with and without bevacizumab were compared. RESULTS In patients with bevacizumab adjuvant therapy, the KPS scores immediately prior to surgery were 90 in 3 cases, 80 in 2, and 70 in 1. The scores in patients without bevacizumab were 50 in 2 and 40 in 4. The 5-ALA fluorescence in patients with bevacizumab was vague in one and none in five. Vague fluorescence was noted in all six patients without bevacizumab. Tumor extraction rates in patients with vs. those without bevacizumab were 97.6% vs. 91.5% by T1-Gd, 95.4% vs. 99.9% by MET, 96.2% vs. 90.2% by FLT, and 97% vs. 92% by FMISO. Corresponding residual volumes (ml) were (0.6 vs. 1.7) for T1-Gd, 1.2 vs. 2.9 for MET, 1.0 vs. 2.1 for FLT, and 0.5 vs. 1.1 for. FLT. Median progression free survival (PFS) was 10.1 vs. 4.9 months; median overall survival (OS) was 15.7 vs. 13.3 months. CONCLUSIONS Neoadjuvant bevacizumab therapy improved KPS at the time of surgery, increased extraction rate, reduced residual tumor volume, and improved PFS and OS prognosis.
Differential characterization of hepatic tumors in MR imaging by burst-released Mn2+-ions from hollow manganese-silicate nanoparticles in the liver
Authors: Jin Goo Kim, Moon-Sun Jang, Nitee Kumari, Jung Kyu Choi, Geun Ho Im, Taewan Kwon, Jung Hee Lee, Won Jae Lee, In Su Lee
Journal: Biomaterials (2019)
Autophagy is critical for group 2 innate lymphoid cell metabolic homeostasis and effector function
Authors: Lauriane Galle-Treger, Benjamin P. Hurrell, Gavin Lewis, Emily Howard, Pedram Shafiei Jahani, Homayon Banie, Babak Razani, Pejman Soroosh, Omid Akbari
Journal: Journal of Allergy and Clinical Immunology (2019)
P2.15-A Panorama Retro: Real World Evaluation of Molecular Testing and Treatment Patterns for EGFR Mutations in Patients with Advanced or Metastatic NSCLC (D133FR00143)
Authors: M. Cuello, C. Martín, S. Sena, J. Cundom, E. Korbenfeld, V. Garcia Cocco, S. Berutti, G. Recondo, H. Perroud, O. Barajas, F. Orlandi, E. Orellana, M. Zapata, S. Arauchan, A. Gómez, C. Bonilla, H. Marcelo, F. Reinhold, S. Goncalves
Journal: Journal of Thoracic Oncology (2019)
Smoking and Personality
Authors: R. E. W. Fisher
Journal: BMJ (1960)

We describe here an interesting case of a 7-day-old male infant brought with parental concerns of inability to extend both knees. Clinical evaluation revealed dysplastic fingernails, bilateral abnormal patellae, triangular lunules in conjunction with pathognomic iliac horns on pelvic radiographs suggesting the possibility of nail-patella syndrome (NPS). Other competing diagnoses with similar phenotypic features were considered and sequentially excluded. A definitive diagnosis was established by the identification of the principal mutation at the LMX1B gene locus of chromosome 9. NPS is seldom diagnosed in neonates due to the heterogeneity of clinical presentations as well as the subtlety of clinical clues in this population. NPS is a dominantly inherited disorder that is predominantly familial in origin and thus carries important implications for the prenatal diagnosis of future pregnancies as well as pre-emptive surveillance of nephropathy in the index child.
Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
Authors: Maria Laura Alberti, Jose María Malet Ruiz, Martin Eduardo Fernández, Leandro Fassola, Fabián Caro, Ivette Buendía Roldán, Francisco Paulin
Journal: Pulmonology (2019)

Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease with limited treatment response and bad prognosis. Sometimes it is indistinguishable from idiopathic pulmonary fibrosis (IPF) becoming one of the main differential diagnosis. The aim of our study is to compare survival and functional decline between these two entities. Survival and functional decline more than 10% in FVC were compared using Kaplan Meier (KM) method between patients with CHP and IPF. Cox proportional hazard analysis was used to identify independent predictors of survival and functional decline. 146 patients were included, 54 with CHP and 92 with IPF. KM rate for 2 years survival was 0.71 (CI 95% 0,6–0,8) for CHP group and 0,83 (CI 95% 0,66 - 0,92) for IPF (p = 0,027). Nevertheless this difference disappeared using Cox proportional hazard analysis, the adjusted HR for survival among CHP patients was 0,53 (CI 95% 0,25–1,15) (p = 0,11). There was no difference in functional evolution between the two groups. KM rate for a decline more than or equal to 10% was 0,64 for CHP (CI 95% 0,43–0,79) and 0,78 for IPF (IC 95% 0,6–0,88) (p = 0,22). This observation did not change after using Cox proportional hazard analysis. Our study shows that both IPF and CHP are fibrosing interstitial diseases with a similar evolution and survival. It might be possible that therapeutic approach in patients with CHP should change in the light of these observations.
Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas
Authors: Xianhuo Wang, Xuhan Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Kai Fu, Huilai Zhang
Journal: Blood (2019)
Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine
Authors: Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Argiris Symeonidis, Ioannis Kotsianidis, Vassiliki Pappa, Athanasios Galanopoulos, Andreas Giannopoulos, Katerina Zoi, Maria Dimou, Elena E. Solomou, Panayiotis Panayiotidis, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou
Journal: Blood (2019)
Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice
Authors: Gary H. Lyman, Kathryn Richert-Boe, Lois Lamerato, Manpreet Kaur, Neel Shah, Tatiana Lawrence, Devi Sundaresan, Amanda Silvia, Ahuva Hanau, Derek Weycker
Journal: Blood (2019)
Pulmonary Vein Varix Mimicking Prostate Cancer Metastasis on 68Ga–Prostate Specific Membrane Antigen-11 PET/CT
Authors: Brian Sgard, Françoise Montravers, Aloÿse Fourquet, Alexandre de la Taille, Mathieu Gauthé
Journal: Clinical Nuclear Medicine (2019)

The use of PET/CT with prostate-specific membrane antigen radioligands for staging prostate cancer patients presenting a biochemical recurrence is increasing. As a consequence, the number of reports of diagnostic pitfall of this imaging modality is also increasing. A 75-year-old man referred for a second episode of biochemical recurrence of prostate cancer presented an isolated intense prostate-specific membrane antigen-11 uptake from a right lung abnormality. This abnormality was suggestive of pulmonary vein varix on contrast-enhanced lung CT. The uptake remained stable 1 month after starting androgen deprivation therapy, which confirmed the diagnostic of pulmonary vein varix.
Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells
Authors: Tuba Özdemi̇r Sanci, Hilal Özdağ, Yasin Köksal, Seda Tasır Yılmaz, Husniye Nese Yarali, Namik Yasar Özbek, Habibe Meltem Özgüner
Journal: Blood (2019)
Respiratory distress syndrome.
Authors: L D Courtney
Journal: BMJ (1977)

Together with colleagues in the University of Dundee I am completing an analysis of views of a one-in-eight sample of Scottish general practitioners concerning the consultation.From this it is clear that GPs (and a sizable proportion in the survey were not college members) do not share Dr Raine Roberts's view (p 508) on the consultation.There is very strong support for helping new entrants to general practice to readjust their approach to clinical medicine to suit the different circum- stances of general practice.
A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies
Authors: Hamid Bolouri, Benjamin K. Johnson, Rhonda E. Ries, Laura Pardo, Tiffany A. Hylkema, Wanding Zhou, Jenny L. Smith, Amanda R. Leonti, Allison Kaeding, Michael R. Loken, Jason E. Farrar, Soheil Meshinchi, Timothy Junius Triche
Journal: Blood (2019)
Pre–Liver Transplant Cardiac Catheterization Is Associated With Low Rate of Myocardial Infarction and Cardiac Mortality
Authors: Issa Kutkut, Rayan Jo Rachwan, Lava R. Timsina, Marwan S. Ghabril, Marco A. Lacerda, Chandrashekhar A. Kubal, Patrick D. Bourdillon, Richard S. Mangus
Journal: Hepatology (2019)

Background and Aims A study at Indiana University demonstrated a reduction in myocardial infarction (MI) incidence with increased frequency of cardiac catheterization (CATH) in liver transplant (LT) candidates. A strict protocol for performing CATH based upon predefined risk factors, rather than noninvasive testing alone, was applied to a subgroup (2009‐2010) from that study. CATH was followed by percutaneous coronary intervention (PCI) in cases of significant coronary artery disease (CAD; ≥50% stenosis). The current study applies this screening protocol to a larger cohort (2010‐2016) to assess post‐LT clinical outcomes. Approach and Results Among 811 LT patients, 766 underwent stress testing (94%) and 559 underwent CATH (69%), of whom 10% had CAD requiring PCI. The sensitivity of stress echocardiography in detecting significant CAD was 37%. Predictors of PCI included increasing age, male gender, and personal history of CAD ( P &lt; 0.05 for all). Compared to patients who had no CATH, patients who underwent CATH had higher mortality ( P = 0.07), and the hazard rates (HR) for mortality increased with CAD severity (normal CATH, HR, 1.35; 95% confidence interval [CI], 0.79‐2.33; P = 0.298; nonobstructive CAD, HR, 1.53; 95% CI, 0.84‐2.77; P = 0.161; and significant CAD, HR, 1.96; 95% CI, 0.93‐4.15; P = 0.080). Post‐LT outcomes were compared to the 2009‐2010 subgroup from the previous study and showed similar 1‐year overall mortality (8% and 6%, P = 0.48), 1‐year MI incidence (&lt;1% and &lt;1%, P = 0.8), and MI deaths as a portion of all deaths (3% and 9%, P = 0.35). Conclusions Stress echocardiography alone is not reliable in screening LT patients for CAD. Aggressive CAD screening with CATH is associated with low rate of MI and cardiac mortality and validates the previously published protocol when extrapolated over a larger sample and longer follow‐up period.
Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo
Authors: Jevgenia Zilberman-Rudenko, Hiroshi Deguchi, Mohammed Hayat, Meenal Shukla, Jennifer Nagrampa Orje, Zihan Guo, Tine Wyseure, Laurent O Mosnier, Owen J T McCarty, Zaverio M. Ruggeri, John H. Griffin
Journal: Blood (2019)
Treatment of Tetanus.
Authors: Matthew M. Smith
Journal: JAMA (1898)

Austin, Texas, July 20, 1898. <h3>To the Editor:</h3> —I send you report of a case of tetanus treated successfully by the use of antitetanic serum. The diagnosis of the case I believe to have been correct, as shown by the history, the symptoms, the response to each dose of the serum, and, further, that the patient lived ten miles in the country, and was not familiar with the symptoms of tetanus. A study of this case shows the immediate response to the antitetanic treatment,<i>i. e.</i>, the pulse, temperature, pain, stiffness and restlessness were all reduced soon after the injection was given. It can further be seen that the dose of serum should have been repeated sooner in this case; but owing to the inaccessibility of the patient it could not be done. There were no unfavorable effects from the use of the serum, not even an eruption. I give
10-Year Update on Study Results Submitted to ClinicalTrials.gov
Authors: Deborah A. Zarin, Kevin M. Fain, Heather D. Dobbins, Tony Tse, Rebecca J. Williams
Journal: New England Journal of Medicine (2019)

10-Year Update on ClinicalTrials.gov A decade after ClinicalTrials.gov launched a database for reporting results of clinical trials, the database includes results of approximately 36,000 trials. Th...
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
Authors: David T Yeung, Naranie Shanmuganathan, Andrew Grigg, Ilona Cunningham, Jake Shortt, Philip Rowling, John Reynolds, Rosemary Anne Harrup, David M Ross, David Kipp, Anthony K Mills, Christopher K Arthur, Anthony P Schwarer, Kathryn Jackson, Nicholas Viiala, Robert Weinkove, Agnes S. M. Yong, Deborah L. White, Susan Branford, Timothy P. Hughes, On Behalf of the ALLG
Journal: Blood (2019)